NL
UTHR icon

NKCFO LLC’s United Therapeutics UTHR Stock Holding History

NKCFO LLC’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-375
Closed -$132K – 129
2024
Q4 		$132K Buy
+375
New +$138K 0.06% 94
2023
Q1 		– Sell
-645
Closed -$179K – 112
2022
Q4 		$179K Buy
645
+100
+18% +$25.2K 0.08% 51
2022
Q3 		$114K Hold
545
– – 0.05% 60
2022
Q2 		$128K Buy
+545
New +$111K 0.05% 65

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

NKCFO LLC's UTHR Position: Q1 2025 in Review

NKCFO LLC sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 375 shares — an estimated $132K sold.

NKCFO LLC first reported a position in UTHR in Q2 2022 and held it in 4 quarters. The position peaked at $179K in Q4 2022. 673 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • NKCFO LLC reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • NKCFO LLC sold 375 United Therapeutics shares in Q1 2025, an estimated $132K.
  • NKCFO LLC first reported a position in United Therapeutics in Q2 2022 and held it in 4 quarters.
  • NKCFO LLC's United Therapeutics position peaked at $179K in Q4 2022.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on NKCFO LLC's 13F filing for Q1 2025, filed 7 May 2025.